Welcome to BioSeeker Group!

Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology

Additional Information

Published Date Mar 17, 2008
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 231
PDF Fact Sheet View Fact Sheet for the report Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$2,450.00

Quick Overview

This report is written for you to identify your competition and understand which targeting strategies are at work within anti-angiogenic drug development in oncology. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversly it may reveal unexpected competition for you.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology.

    To find out more about Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Executive Summary

There is a plethora of new anti-angiogenic drugs in development. The potential to block tumor growth and metastases by angiogenesis inhibition represents an intriguing therapeutic strategy for the treatment of cancer and never before have we seen as many anti-angiogenic drugs in clinical trials.

This report is written for you to identify your competition and understand which targeting strategies are at work within anti-angiogenic drug development in oncology. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversly it may reveal unexpected competition for you.
First, BioSeeker has surveyed anti-angiogenic drugs in oncology and identified 108 drug targets, belonging to 123drugs. This report, Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology, is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of new anti-angiogenic drugs in oncology.

In the report, BioSeeker reports on 88 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 123 anti-angiogenic drugs designed for the treatment of 44 different cancer indications. The highest degree of distinctiveness among anti-angiogenic drugs is achieved by sorting each of them according to targeted cancer indication, drug target mix, and drug compound type. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development.

To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified targets of anti-angiogenic drugs. No less than 162 protein-protein interactions were recognized among and between 86 of the 108 included anti-angiogenic drug targets.

Why You Should Own Your Own Copy of this Report:

  • 230+ pages, with almost a hundred different tables and figures. Includes more than 1,500 active links to related resources on the Internet
  • 123 anti-angiogenic drugs, under development by 90 investigators, are included, covering more than 361 developmental projects in cancer
  • 108 Unique, in-depth, drug target profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other anti-angiogenic drug targets, linked cancer indications, drugs under development, compound types, presence in the Cancer Genome Project etc.
  • Unique 231 drug-protein target interactome analysis
  • Unique drug target combination breakdown into 44 different cancer types
  • Covers 88 unique drug target combinations of anti-angiogenic drugs
  • 162 protein-protein interactions among and between anti-angiogenic drug targets
  • Pathway grouping of anti-angiogenic drug targets
  • Pin-point which competitor drugs’ clinical out-come may have bearing on your own drug development
  • Who are working on sequels to blockbuster drugs
  • Locate white-spots in the competitive landscape, giving you little or no competition

In all, this report is a serious reference for any professional interested in the development of oncology drug targets and the selection/validation of targeting strategies.

1 Executive Summary

2 About Cancer Highlights

3 Methodologies

4 4.1 List of Figures
4.2 List of Tables

5 How to Use this Report

6 Anti-Angiogenic Drug Compound Types and Sub-cellular Localizations of Targets

7 The Cancer Genome Project and Angiogenesis Drug Targets
7.1 Anti-Angiogenic Drug Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer

8 Protein Expression Profiles of Anti-Angiogenic Drug Targets in Human
8.1 Expression in Normal Tissues and Cancer Tissues
8.2 Expression in Human Cancer Cell Lines and Primary Cells

9 Pathway Analysis of Anti-Angiogenic Drugs

10 Protein-Protein Interactions Among Identified Anti-Angiogenic Drug Targets

11 Available Biological Structure Data on Anti-Angiogenic Drug Targets

12 Drug Target Profiles of Anti-angiogenesis Drug Targets in Oncology
12.11 Carboxy-Lyase Activity
12.12 Catalytic Activity
12.13 Cell Adhesion Molecule Activity
12.14 Chaperone Activity
12.15 Cofactor Binding
12.16 Cysteine-Type Peptidase Activity
12.17 Cytokine Activity
12.18 DNA Topoisomerase Activity
12.19 DNA-Directed DNA Polymerase Activity
12.11.0 Extracellular Matrix Structural Constituent
12.11.1 G-Protein Coupled Receptor Activity
12.11.2 Growth Factor Activity
12.11.3 GTPase Activity
12.11.4 Hydrolase Activity
12.11.5 Kinase Activity
12.11.6 Lipid Kinase Activity
12.11.7 Metallopeptidase Activity
12.11.8 Molecular Function Unknown
12.11.9 Motor Activity
12.12.0 Peptidase Activity
12.12.1 Protease Inhibitor Activity
12.12.2 Protein Serine/Threonine Kinase Activity
12.12.3 Protein-Tyrosine Kinase Activity
12.12.4 Receptor Activity
12.12.5 Receptor Binding
12.12.6 Serine-Type Peptidase Activity
12.12.7 Structural Constituent of Cytoskeleton
12.12.8 Superoxide Dismutase Activity
12.12.9 Transcription Factor Activity
12.13.0 Transcription Regulator Activity
12.13.1 Translation Regulator Activity
12.13.2 Transmembrane Receptor Activity
12.13.3 Transmembrane Receptor Protein Tyrosine Kinase Activity
12.13.4 Transporter Activity

13 The Drug-Protein Interactome of Anti-Angiogenic Drugs

14 The Progression and Maturity of Anti-Angiogenic Drug Target Combinations
14.1 Target Profiles of Anti-Angiogenic Drugs on the Market
14.2 New Anti-Angiogenic Drug Target Combinations in Phase III Clinical Development
14.3 New Anti-Angiogenic Drug Target Combinations in Phase II Clinical Development
14.4 New Anti-Angiogenic Drug Target Combinations Phase I Clinical Development
14.5 New Anti-Angiogenic Drug Target Combinations in Preclinical Development
14.6 Development Profiles of All Identified Anti-Angiogenic Drug Target Combinations

15 Anti-Angiogenic Drug Target Mix by Cancer Indication
15.1 Adrenal Cancer
15.2 Biliary Cancer
15.3 Bladder Cancer
15.4 Bone Cancer
15.5 Brain Cancer
15.6 Breast Cancer
15.7 Carcinoid Tumor
15.8 Cervical Cancer
15.9 Chemotherapy-Induced Infection
15.10 Colorectal Cancer
15.11 Endometrial Cancer
15.12 Fallopian Tube Cancer
15.13 Gastrointestinal Cancer
15.13.1 Gastrointestinal Stomach Cancer
15.13.2 Gastrointestinal Stromal Cancer
15.14 Head and Neck Cancer
15.15 Leukemia
15.15.1 Acute Lymphocytic Leukemia
15.15.2 Acute Myelogenous Leukemia
15.15.3 Chronic Lymphocytic Leukemia
15.15.4 Chronic Myelogenous Leukemia
15.16 Liver Cancer
15.17 Lung Cancer
15.17.1 Non-Small Cell Lung Cancer
15.17.2 Small Cell Lung Cancer
15.18 Lymphoma
15.18.1 B-Cell Lymphoma
15.18.2 Hodgkin’s Lymphoma
15.18.3 Non-Hodgkin’s Lymphoma
15.19 Melanoma
15.20 Mesothelioma
15.21 Myelodysplastic Syndrome
15.22 Myeloma
15.23 Nasopharyngeal Cancer
15.24 Oesophageal Cancer
15.25 Ovarian Cancer
15.26 Pancreatic Cancer
15.27 Peritoneal Cancer
15.28 Prostate Cancer
15.29 Renal Cancer
15.30 Sarcoma
15.30.1 Leiomyo Sarcoma
15.31 Squamous Cell Cancer
15.32 Thyroid Cancer

16 Anti-Angiogenic Drugs and Their Targets by Companies
16.1 Australia
16.2 Austria
16.3 Belgium
16.4 Canada
16.5 China
16.6 Denmark
16.7 France
16.8 Germany
16.9 Israel
16.10 Japan
16.11 Netherlands
16.12 South Korea
16.13 Spain
16.14 Sweden
16.15 Switzerland
16.16 United Kingdom
16.17 USA

17 Disclaimer

18 Drug Index

19 Company Index

4.1 List of Figures
Figure 1: Distribution of Compound Types Among Anti-Angiogenic Drugs
Figure 2: Primary Sub-cellular Localization of Drug Targets
Figure 3: Visualization of Protein-Protein Interactions Among Anti-Angiogenic Drug Targets
Figure 4: The Drug-Protein Interactome of Anti-Angiogenic Drugs
Figure 5: Direct Head-to-Head Targeting Interactome of Anti-Angiogenic Drugs

4.2 List of Tables
Table 1: Compound Type Versus Primary and Alternate Localization of Drug Target
Table 2: Drug Targets of Anti-Angiogenic Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
Table 3: Available Protein Expression Profiles of Anti-Angiogenic Drug Targets
Table 4: Pathway Summary
Table 5: Drug Targets Without any Identified Assigned Pathways
Table 6: Pathway Profile According to BioCarta of the Anti-Angiogenic Drug Targets
Table 7: Pathway Profile According to KEGG of the Anti-Angiogenic Drug Targets
Table 8: Anti-Angiogenic Drugs Targeting Major Singaling Pathways
Table 9: Protein-Protein Interactions Among Anti-Angiogenic Drug Targets
Table 10: Number of Available Biological Structures on Anti-Angiogenic Drug Targets
Table 11: Overview of Drug Target Profile Themes
Table 12: Drug-Protein Clusters in the Anti-Angiogenic Interactome
Table 13: Fall Out in Terms of the Total Number of Drug Target Mixes, Drugs, Developmental Projects, and the Presence of New Drug Target Mixes by Developmental Stage
Table 14: Target Profiles of Anti-Angiogenic Drugs on the Market
Table 15: New Anti-Angiogenic Drug Target Combinations in Phase III Clinical Development
Table 16: New Anti-Angiogenic Drug Target Combinations in Phase II Clinical Development
Table 17 New Anti-Angiogenic Drug Target Combinations Phase I Clinical Development
Table 18: New Anti-Angiogenic Drug Target Combinations in Preclinical Development
Table 19: The Progression, Maturity and Comptitive Comparison of Anti-Angiogenic Drug Target Mixes in Development
Table 20: Number of Unique Anti-angiogenic Drug Target Mixes Reported by Cancer Indication
Table 21: The Competitive Situation on Bevacizumab (Avastin)
Table 22: Anti-angiogenic Drug Target Mix for the Treatment of Adrenal Cancer According to the Compound Type and Developmental Stage of Drug
Table 23: Anti-angiogenic Drug Target Mix for the Treatment of Biliary Cancer According to the Compound Type and Developmental Stage of Drug
Table 24: Anti-angiogenic Drug Target Mix for the Treatment of Bladder Cancer According to the Compound Type and Developmental Stage of Drug
Table 25: Anti-angiogenic Drug Target Mix for the Treatment of Bone Cancer According to the Compound Type and Developmental Stage of Drug
Table 26: Anti-angiogenic Drug Target Mix for the Treatment of Brain Cancer According to the Compound Type and Developmental Stage of Drug
Table 27: Anti-angiogenic Drug Target Mix for the Treatment of Breast Cancer According to the Compound Type and Developmental Stage of Drug
Table 28: Anti-angiogenic Drug Target Mix for the Treatment of Carcinoid Tumor According to the Compound Type and Developmental Stage of Drug
Table 29: Anti-angiogenic Drug Target Mix for the Treatment of Cervical Cancer According to the Compound Type and Developmental Stage of Drug
Table 30: Anti-angiogenic Drug Target Mix for the Treatment of Chemotherapy-induced Infection According to the Compound Type and Developmental Stage of Drug
Table 31: Anti-angiogenic Drug Target Mix for the Treatment of Colorectal Cancer According to the Compound Type and Developmental Stage of Drug
Table 32: Anti-angiogenic Drug Target Mix for the Treatment of Endometrial Cancer According to the Compound Type and Developmental Stage of Drug
Table 33: Anti-angiogenic Drug Target Mix for the Treatment of Fallopian Tube Cancer According to the Compound Type and Developmental Stage of Drug
Table 34: Anti-angiogenic Drug Target Mix for the Treatment of Gastrointestinal Cancer (General) According to the Compound Type and Developmental Stage of Drug
Table 35: Anti-angiogenic Drug Target Mix for the Treatment of Gastrointestinal Stomach Cancer According to the Compound Type and Developmental Stage of Drug
Table 36: Anti-angiogenic Drug Target Mix for the Treatment of Gastrointestinal Stromal Cancer According to the Compound Type and Developmental Stage of Drug
Table 37: Anti-angiogenic Drug Target Mix for the Treatment of Head and Neck Cancer According to the Compound Type and Developmental Stage of Drug
Table 38: Anti-angiogenic Drug Target Mix for the Treatment of Leukemia (General) According to the Compound Type and Developmental Stage of Drug
Table 39: Anti-angiogenic Drug Target Mix for the Treatment of Acute Lymphocytic Leukemia According to the Compound Type and Developmental Stage of Drug
Table 40: Anti-angiogenic Drug Target Mix for the Treatment of Acute Myelogenous Leukemia According to the Compound Type and Developmental Stage of Drug
Table 41: Anti-angiogenic Drug Target Mix for the Treatment of Chronic Lymphocytic Leukemia Cancer According to the Compound Type and Developmental Stage of Drug
Table 42: Anti-angiogenic Drug Target Mix for the Treatment of Chronic Myelogenous Leukemia Cancer According to the Compound Type and Developmental Stage of Drug
Table 43: Anti-angiogenic Drug Target Mix for the Treatment of Liver Cancer According to the Compound Type and Developmental Stage of Drug
Table 44: Anti-angiogenic Drug Target Mix for the Treatment of Lung Cancer (General) According to the Compound Type and Developmental Stage of Drug
Table 45: Anti-angiogenic Drug Target Mix for the Treatment of Non-Small Cell Lung Cancer According to the Compound Type and Developmental Stage of Drug
Table 46: Anti-angiogenic Drug Target Mix for the Treatment of Small Cell Lung Cancer According to the Compound Type and Developmental Stage of Drug
Table 47: Anti-angiogenic Drug Target Mix for the Treatment of Lymphoma (General) According to the Compound Type and Developmental Stage of Drug
Table 48: Anti-angiogenic Drug Target Mix for the Treatment of B-Cell Lymphoma According to the Compound Type and Developmental Stage of Drug
Table 49: Anti-angiogenic Drug Target Mix for the Treatment of Hodgkin’s Lymphoma According to the Compound Type and Developmental Stage of Drug
Table 50: Anti-angiogenic Drug Target Mix for the Treatment of Non-Hodgkin’s Lymphoma According to the Compound Type and Developmental Stage of Drug
Table 51: Anti-angiogenic Drug Target Mix for the Treatment of Melanoma According to the Compound Type and Developmental Stage of Drug
Table 52: Anti-angiogenic Drug Target Mix for the Treatment of Mesothelioma According to the Compound Type and Developmental Stage of Drug
Table 53: Anti-angiogenic Drug Target Mix for the Treatment of Myelodysplastic Syndrome According to the Compound Type and Developmental Stage of Drug
Table 54: Anti-angiogenic Drug Target Mix for the Treatment of Myeloma According to the Compound Type and Developmental Stage of Drug
Table 55: Anti-angiogenic Drug Target Mix for the Treatment of Nasopharyngeal Cancer According to the Compound Type and Developmental Stage of Drug
Table 56: Anti-angiogenic Drug Target Mix for the Treatment of Oesophageal Cancer According to the Compound Type and Developmental Stage of Drug
Table 57: Anti-angiogenic Drug Target Mix for the Treatment of Ovarian Cancer According to the Compound Type and Developmental Stage of Drug
Table 58: Anti-angiogenic Drug Target Mix for the Treatment of Pancreatic Cancer According to the Compound Type and Developmental Stage of Drug
Table 59: Anti-angiogenic Drug Target Mix for the Treatment of Peritoneal Cancer According to the Compound Type and Developmental Stage of Drug
Table 60: Anti-angiogenic Drug Target Mix for the Treatment of Prostate Cancer According to the Compound Type and Developmental Stage of Drug
Table 61: Anti-angiogenic Drug Target Mix for the Treatment of Renal Cancer According to the Compound Type and Developmental Stage of Drug
Table 62: Anti-angiogenic Drug Target Mix for the Treatment of Sarcoma (General) According to the Compound Type and Developmental Stage of Drug
Table 63: Anti-angiogenic Drug Target Mix for the Treatment of Leiomyo Sarcoma According to the Compound Type and Developmental Stage of Drug
Table 64: Anti-angiogenic Drug Target Mix for the Treatment of Squamous Cell Cancer According to the Compound Type and Developmental Stage of Drug
Table 65: Anti-angiogenic Drug Target Mix for the Treatment of Thyroid Cancer According to the Compound Type and Developmental Stage of Drug
Table 66: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Australia
Table 67: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Austria
Table 68: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Belgium
Table 69: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Canada
Table 70: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in China
Table 71: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Denmark
Table 72: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in France
Table 73; Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Germany
Table 74: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Israel
Table 75: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Japan
Table 76: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in the Netherlands
Table 77: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in South Korea
Table 78: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in South Korea
Table 79: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Sweden
Table 80: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Switzerland
Table 81: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in United Kingdom
Table 82: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in USA

This report covers in-depth the following 90 investigators:
Abbott
Abraxis BioScience
Access
Adherex
Advantagene
Aeterna Zentaris
Agennix
Aida Pharmaceuticals
Alnylam
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amphora
AngioChem
Angiogen
Angiogenex
Antigenics
Antisoma
Ariad
Array BioPharma
AstraZeneca
Attenuon
Austrianova
Bayer
BioAlliance Pharma
BioInvent
Boehringer Ingelheim
Bolder BioTechnology
Bristol-Myers Squibb
Celgene
Choongwae
CovX
Cytochroma
Dendreon
Dyax
Eisai
Eli Lilly
EntreMed
Exelixis
ExonHit Therapeutics
Genentech
Genmab
Genzyme
GlaxoSmithKline
GlycoGenesys
Green Cross
ImClone Systems
Introgen Therapeutics
Isis Pharmaceuticals
Johnson & Johnson
KAI Pharmaceuticals
Karus Therapeutics
Kirin Pharma
Locus Pharmaceuticals
MAT Biopharma
MediGene
Merck KGaA
Novartis
Novelix
Onconova
OSI Pharmaceuticals
OXiGENE
PDL BioPharma
Pepscan Systems
Peptech
Peregrine Pharmaceuticals
Pfizer
Pharmacyclics
PharmaMar
Pharminox
PIERIS Proteolab
Progen
Protein Sciences
PTC Therapeutics
Regeneron
Rigel
Santaris Pharma
SciClone Pharmaceuticals
Semafore Pharmaceuticals
Simcere Pharmaceuticals
SRI International
Switch Pharma
SynDevRx
ThromboGenics
ToolGen
Tracon Pharmaceuticals
UCB
Vascular Biogenics
Wilex
Wyeth
Includes a total of 123 angiogenesis drugs in oncology. Some examples are:
bevacizumab
cediranib
cilengitide
combretastatin A-4 prodrug
deforolimus
Endostatin
enzastaurin hydrochloride
everolimus
INGN-241
pazopanib hydrochloride
razoxane
sorafenib tosylate
thymalfasin
vandetanib
vatalanib

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology.
    To find out more about Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


The Commercial Success of Cancer Therapeutic Antibodies - The Formation of a Second Wave
The blockbuster drugs Rituxan, Avastin, and Erbitux have change the way the industry looks upon antibody treatment of cancer in the same way that Taxol changed the way pharmaceutical companies look at the possibilities in the field of cancer therapeutics. Learn More


Cancer Vaccines: From First-in-Class to Best-in-Class?
In-depth pipeline analytics of cancer vaccine drugs showing you where the competition is, what is first-in-class and is first-in-class the best-in-class?, Indication expansion opportunities and much more Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Leukemia, Cancer Vaccines and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Peptides). Learn More


Triple Analysis: Lymphoma, Prostate Cancer and Antibodies
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Prostate Cancer and by the compound strategy of Antibodies. Learn More